Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection

Vaccine

Volumn 26, Issue 45, 2008, Pages 5760-5766

  Cui, Xiaohong ^a   Meza, Benjamin P ^a   Adler, Stuart P ^a   McVoy, Michael A ^a  

^a Med Coll Va Campus Virginia Commonwealth Univ ^*  (United States)

Author keywords

Cytomegalovirus; Neutralizing antibody; Vaccines

Indexed keywords

ANTISERUM; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN; GLYCOPROTEIN GB MF59 VACCINE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG TREATMENT FAILURE; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRION; VIRUS ENTRY; VIRUS STRAIN;

ANTIBODIES, VIRAL; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; NEUTRALIZATION TESTS; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS INTERNALIZATION;

EID: 53149090132     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.092     Document Type: Article

References (34)

1. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., and Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326 10 (1992) 663-667
2. In: Stratton K.R., Durch S.J., and Lawrence R.S. (Eds). Vaccines for the 21st century: a tool for decision-making (2000), National Academy Press, Washingto D.C.
3. Marshall G.S., Rabalais G.P., Stout G.G., and Waldeyer S.L. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlates with neutralizing activity. J Infect Dis 165 2 (1992) 381-384
4. Urban M., Klein M., Britt W.J., Hassfurther E., and Mach M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77 Pt 7 (1996) 1537-1547
5. Shimamura M., Mach M., and Britt W.J. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80 9 (2006) 4591-4600
6. Adler S.P., Hempfling S.H., Starr S.E., Plotkin S.A., and Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 17 3 (1998) 200-206
7. Pass R.F., Duliege A.M., Boppana S., et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180 4 (1999) 970-975
8. Wang D., and Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102 50 (2005) 18153-18158
9. Hahn G., Revello M.G., Patrone M., et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78 18 (2004) 10023-10033
10. Ryckman B.J., Jarvis M.A., Drummond D.D., Nelson J.A., and Johnson D.C. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 80 2 (2006) 710-722
11. Adler B., Scrivano L., Ruzcics Z., Rupp B., Sinzger C., and Koszinowski U. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 87 Pt 9 (2006) 2451-2460
12. Gerna G., Sarasini A., Patrone M., et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89 Pt 4 (2008) 853-865
13. Patrone M., Secchi M., Bonaparte E., Milanesi G., and Gallina A. Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells. J Virol 81 20 (2007) 11479-11488
14. Dolan A., Cunningham C., Hector R.D., et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol 85 Pt 5 (2004) 1301-1312
15. Patrone M., Secchi M., Fiorina L., Ierardi M., Milanesi G., and Gallina A. Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J Virol 79 13 (2005) 8361-8373
16. Wang J.B., Adler S.P., Hempfling S., et al. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis 174 2 (1996) 387-392
17. Adler S.P., and McVoy M. Detection of cytomegalovirus antibody by enzyme immunoassay and lack of evidence for an effect resulting from strain heterogeneity. J Clin Microbiol 24 5 (1986) 870-872
18. Wang D., Bresnahan W., and Shenk T. Human cytomegalovirus encodes a highly specific RANTES decoy receptor. Proc Natl Acad Sci USA 101 47 (2004) 16642-16647
19. Wang D., and Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 79 16 (2005) 10330-10338
20. Hahn G., Jarosch M., Wang J.B., Berbes C., and McVoy M.A. Tn7-mediated introduction of DNA sequences into bacmid-cloned cytomegalovirus genomes for rapid recombinant virus construction. J Virol Methods 107 2 (2003) 185-194
21. Cui X., McGregor A., Schleiss M.R., and McVoy M.A. Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication. J Virol Methods 149 2 (2008) 231-239
22. Abai A.M., Smith L.R., and Wloch M.K. Novel microneutralization assay for HCMV using automated data collection and analysis. J Immunol Methods 322 1-2 (2007) 82-93
23. Adler S.P., Chandrika T., Lawrence L., and Baggett J. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr Infect Dis 2 2 (1983) 114-118
24. Yeager A.S., Grumet F.C., Hafleigh E.B., Arvin A.M., Bradley J.S., and Prober C.G. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 98 2 (1981) 281-287
25. Nigro G., Adler S.P., La Torre R., and Best A.M. Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection. N Engl J Med 353 13 (2005) 1350-1362
26. Rasmussen L., Matkin C., Spaete R., Pachl C., and Merigan T.C. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis 164 5 (1991) 835-842
27. Keay S., and Baldwin B. Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment. J Virol 65 9 (1991) 5124-5128
28. Ryckman B.J., Rainish B.L., Chase M.C., et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol (2007)
29. Wang D., Yu Q.C., Schroer J., Murphy E., and Shenk T. Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc Natl Acad Sci USA 104 50 (2007) 20037-20042
30. Gerna G., Percivalle E., Lilleri D., et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 86 Pt 2 (2005) 275-284
31. Sinzger C. Entry route of HCMV into endothelial cells. J Clin Virol 41 3 (2008) 174-179
32. Plotkin S.A., Smiley M.L., Friedman H.M., et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1 8376 (1984) 528-530
33. Adler S.P., Starr S.E., Plotkin S.A., et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age [published erratum appears in J Infect Dis 1995 Apr;171(4):1080]. J Infect Dis 171 1 (1995) 26-32
34. Pass, R., Zhang, C., Simpson, T. et al. Cytomegalovirus (CMV) Envelope Glycoprotein B (gB) Vaccine in Young Women. in Infectious Diseases Society of America, San Diego California, 2007.